Jae Hoon Chung

Prof. Jae Hoon Chung

Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in Endocrine-Related Cancer
Verified
Journal Article
Closed access
PDF file
SASoomin Ahn
Soomin Ahn
TKTae Hyuk Kim
Tae Hyuk Kim
SKSun Wook Kim
Sun Wook Kim
CKChang Seok Ki
Chang Seok Ki
HJHye Won Jang
Hye Won Jang
JCJae Hoon Chung
Jae Hoon Chung
PD-L1 expression is being considered a potential biomarker for response of anti-PD-1 or anti-PD-L1 agents in various tumors. The reported frequency of PD-L1 positivity varies in thyroid carcinomas, and multiple factors may contribute to the variability in PD-L1 positivity. We evaluated the PD-L1 expression in various thyroid cancers on a large scale. A total of 407 primary thyroid cancers with a median 13.7-year of follow-up were included. We evaluated the frequency of PD-L1 expression using a rabbit monoclonal antibody (clone SP142). In addition, we analyzed the relationships between PD-L1 expression and clinicopathologic factors, includingTERTpromoter, BRAFstatus and disease progression. Tumoral PD-L1 was expressed in 6.1% of papillary thyroid carcinomas, 7.6% of follicular thyroid carcinomas and 22.2% of anaplastic thyroid carcinomas. The distribution of PD-L1 positivity was different according to cancer histology types (P < 0.001). All PD-L1-positive cases of follicular thyroid carcinoma and anaplastic thyroid carcinoma showed strong intensity. The proportions of positivity in PD-L1 positive anaplastic thyroid carcinomas were more than 80%. PD-L1 in immune cells was positive in 28.5% of papillary thyroid carcinoma, 9.1% of follicular thyroid carcinomas and 11.1% of anaplastic thyroid carcinomas. There was no significant association between clinicopathologic variables, disease progression, oncogenic mutation and PD-L1 expression. PD-L1 was highly expressed in a subset of patients with advanced thyroid cancer, such as follicular and anaplastic thyroid carcinoma. Identification of PD-L1 expression may have direct therapeutic relevance to patients with refractory thyroid cancer.

8 November 2012 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
HKHye Jeong Kim
Hye Jeong Kim
SSSeo Young Sohn
Seo Young Sohn
HJHye Won Jang
Hye Won Jang
SKSun Wook Kim
Sun Wook Kim
JCJae Hoon Chung
Jae Hoon Chung

1 January 2017 in Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
WKWon Gu Kim
Won Gu Kim
GWGyeongji Woo
Gyeongji Woo
HKHyejin Kim
Hyejin Kim
YCYumi Cho
Yumi Cho
TKTae Hyuk Kim
Tae Hyuk Kim
JCJae Hoon Chung
Jae Hoon Chung
Kim WG, et al. Endocrinol Metab. 2017 Mar;32(1):106-114. https://doi.org/10.3803/EnM.2017.32.1.106

1 October 2016 in Endocrine-Related Cancer
Verified
Journal Article
Closed access
PDF file
TKTae Hyuk Kim
Tae Hyuk Kim
YKYoung-Eun Kim
Young-Eun Kim
SASoomin Ahn
Soomin Ahn
JKJi-Youn Kim
Ji-Youn Kim
CKChang-Seok Ki
Chang-Seok Ki
JCJae Hoon Chung
Jae Hoon Chung
TERT promoter mutations are emerging prognostic biomarkers in multiple cancers and are found in highly aggressive thyroid cancer. Our aim is to investigate the prognostic value of these mutations for the outcome of thyroid cancer-related mortality in a large cohort of thyroid cancer patients. This was a retrospective study of 409 patients (393 with differentiated thyroid cancer) with a median age of 44 years (range 16–81 years) and median follow-up of 13 years (interquartile range 11–16 years). Analyses of associations between mutational status and various clinicopathological variables were performed. TERT promoter mutations were identified in 32 (9.8%) papillary, 11 (16.7%) follicular and seven (43.8%) poorly differentiated/anaplastic thyroid cancer patients. The presence of TERT promoter mutations was associated with factors such as increased age (P < 0.001), extrathyroidal invasion (P = 0.01), increased stage at diagnosis (P < 0.001) and dedifferentiated histological type (P = 0.001). A TERT promoter mutation was independently associated with poorer overall survival in patients with differentiated thyroid cancer (10-year survival rate, 66.2% vs 98.3% for wild type; adjusted HR, 7.18; 95% CI: 2.77–18.59) and in patients with papillary cancer (74.2% vs 99.3%; 14.20; 3.03–66.68). Concomitant TERT and BRAF mutations worsened the survival rate of patients with papillary cancer (82.6% vs 99.4% for exclusively BRAF mutation alone; 5.62; 1.85–17.09). In conclusion, the presence of TERT promoter mutations is independently associated with increased mortality in patients with differentiated thyroid cancer. The results suggest that inclusion of TERT promoter mutation analysis with conventional clinicopathological evaluation can lead to better prognostication and management for individual patients.

1 August 2017 in Oral Oncology
Verified
Journal Article
Closed access
TKTae Hyuk Kim
Tae Hyuk Kim
YKYoung Nam Kim
Young Nam Kim
HKHye In Kim
Hye In Kim
SPSo Young Park
So Young Park
JCJun-Ho Choe
Jun-Ho Choe
JCJae Hoon Chung
Jae Hoon Chung

20 March 2018 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
GSGihyeon Seo
Gihyeon Seo
TKTae Hyuk Kim
Tae Hyuk Kim
JCJae Hoon Chung
Jae Hoon Chung
Untreated or insufficiently treated Graves disease in pregnancy may pose risks to both mother and fetus. Antithyroid drugs (ATDs) are the treatment mainstay, but the potential teratogenic effect of these drugs has prompted clinicians to question the safe management of this vulnerable population. To examine the association between maternal prescriptions for ATDs and congenital malformations in live births. Nationwide cohort study. Korean National Health Insurance database. A cohort of 2 886 970 completed pregnancies linked to live-born infants in 2 210 253 women between 2008 and 2014. Maternal prescriptions for ATDs in the first trimester. The risk for overall and organ-specific congenital malformations in offspring, with logistic regression models used to control for potential confounders. 12 891 pregnancies (0.45%) were exposed to ATDs during the first trimester. The prevalence of malformations in exposed offspring was 7.27%, compared with 5.94% in offspring of women who were not prescribed ATDs during pregnancy (P < 0.001) (adjusted odds ratio, 1.19 [95% CI, 1.12 to 1.28]). Absolute increases in the prevalence of congenital malformations per 1000 live births were 8.81 cases (CI, 3.92 to 13.70 cases) for propylthiouracil alone, 17.05 cases (CI, 1.94 to 32.15 cases) for methimazole (MMI) alone, and 16.53 cases (CI, 4.73 to 28.32 cases) for propylthiouracil and MMI, compared with pregnancies without ATD prescriptions. In the MMI group, a high cumulative dose (>495 mg) during the first trimester was associated with an increased risk for malformations compared with a low dose (1 to 126 mg) (adjusted odds ratio, 1.87 [CI, 1.06 to 3.30]). The study used a prescription claims database to assess ATD exposure. Exposure to ATDs during the first trimester was associated with increased risk for congenital malformations, particularly for pregnancies in which women received prescriptions for MMI or both ATDs. None.